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BACKGROUND AND PURPOSE
The discovery that flavonoids are capable of inhibiting platelet function has led to their investigation as potential
antithrombotic agents. However, despite the range of studies on the antiplatelet properties of flavonoids, little is known about
the mechanisms by which flavonoids inhibit platelet function. In this study, we aimed to explore the pharmacological effects
of a polymethoxy flavonoid, nobiletin, in the modulation of platelet function.
EXPERIMENTAL APPROACH
The ability of nobiletin to modulate platelet function was explored by using a range of in vitro and in vivo experimental
approaches. Aggregation, dense granule secretion and spreading assays were performed using washed platelets. Fibrinogen
binding, α-granule secretion and calcium mobilization assays were performed using platelet-rich plasma and whole blood was
used in impedance aggregometry and thrombus formation experiments. The effect of nobiletin in vivo was assessed by
measuring tail bleeding time using C57BL/6 mice.
KEY RESULTS
Nobiletin was shown to suppress a range of well-established activatory mechanisms, including platelet aggregation, granule
secretion, integrin modulation, calcium mobilization and thrombus formation. Nobiletin extended bleeding time in mice and
reduced the phosphorylation of PKB (Akt) and PLCγ2 within the collagen receptor (glycoprotein VI)-stimulated pathway, in
addition to increasing the levels of cGMP and phosphorylation of vasodilator-stimulated phosphoprotein, a protein whose
activity is associated with inhibitory cyclic nucleotide signalling.
CONCLUSIONS AND IMPLICATIONS
This study provides insight into the underlying molecular mechanisms through which nobiletin modulates haemostasis and
thrombus formation. Therefore, nobiletin may represent a potential antithrombotic agent of dietary origins.
Abbreviations
GPVI, glycoprotein VI; sGC, soluble guanylate cyclase; VASP, vasodilator-stimulated phosphoprotein
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Introduction
Platelet activation is initiated upon binding of various
ligand molecules to their cognate cell surface receptors,
which trigger intracellular signalling cascades that lead to
shape change, release of granule contents, thromboxane A2
(TXA2) synthesis and release and thrombus formation
(Gibbins, 2004). A number of currently available anti-
thrombotic drugs (e.g. aspirin and clopidogrel) are ham-
pered by associated side effects including severe bleeding
(Barrett et al., 2008; Mackman, 2008; Michelson, 2008), and
therefore, the development of safer, more efficacious and
target-specific drugs to prevent thrombosis is a pressing pri-
ority. The association between diet and cardiovascular
disease is well established (Wright et al., 2012). Epidemio-
logical studies (Middleton et al., 2000; Joshipura et al., 2001;
Hubbard et al., 2004; Benavente-Garcia and Castillo, 2008;
Hooper et al., 2012) have suggested that regular intake of
foods rich in flavonoids can reduce cardiovascular disease
risks. Indeed, dietary flavonoids have been shown to inhibit
platelet function, reduce lipid levels and maintain vascular
integrity, which may underpin a reduced risk of cardiovas-
cular diseases. The complex nature of the mechanism of
action of plant flavonoids on the cardiovascular system
including platelets has initiated research to better under-
stand the basis of the relationship between these dietary
components and cardiovascular health in order to develop
more effective strategies to prevent or treat thrombotic dis-
eases (Wright et al., 2012).
Since extracts from citrus fruits, particularly lemons
(Citrus limon) are widely used in traditional medications in
India and China, we sought to explore the importance of
flavonoids which are abundant in citrus fruits on platelet
function. Nobiletin is a highly abundant flavonoid present in
these and is structurally similar to tangeretin, another abun-
dant flavonoid in such sources (Benavente-Garcia and
Castillo, 2008). Nobiletin has been shown to have several
beneficial effects on different cell types including anti-
proliferative and anti-apoptotic properties on cancer cells
(Akao et al., 2008; Chen et al., 2014), and inhibitory effects on
inflammation (Wu et al., 2006). Nobiletin has been shown to
reduce the adhesive properties of platelets (Sempinska et al.,
1977; Robbins, 1988), although the mechanisms through
which this occurs and its potential to reduce thrombus for-
mation have not been explored previously. In a previous
study, we reported that tangeretin inhibits platelet function
and thrombus formation via elevation of cGMP and inhibi-
tion of PI3K signalling (Vaiyapuri et al., 2013). In this study,
we demonstrated that nobiletin is a potent inhibitor of plate-
let function that acts through similar effects on platelet func-
tion, and established these mechanisms as commonmodes of
action which flavonoids may share in order to modulate the
function of these cells.
Methods
Detailed methods for immunoblotting analysis, cyclic
nucleotide, flow cytometry, clot retraction, platelet spread-
ing, in vitro thrombus formation and tail bleeding assays are
provided in Supporting Information Appendix S1.
The animal welfare and ethical statement
All animals (C57BL/6 mice) were used following appropriate
approval from the University of Reading Local Ethics Review
Panel and a license from the British Home Office accordance
with the Animal (Scientific Procedures) Act 1986. All studies
involving animals are reported in accordance with the
ARRIVE guidelines for reporting experiments involving
animals (Kilkenny et al., 2010; McGrath et al., 2010). Nobile-
tin or vehicle control was administered blindly, and the
number of mice required was calculated based on previous
studies within the authors’ laboratory (Vaiyapuri et al., 2013).
Every animal used in the experiments was included in the
analysis (no exclusions were made). There were no adverse
effects observed in mice infused with nobiletin.
Tables of Links
TARGETS
Catalytic receptorsa Enzymesb
Integrin α2β1 COX
Integrin αIIbβ3 PI3K
Collagen receptor PKB (Akt)
PKG
PLCγ2
sGC
Syk
LIGANDS
ADP Luteolin
Apigenin LY294002
Aspirin Nitric oxide (NO)
ATP ODQ
cGMP Quercetin
Clopidogrel Thrombin
Collagen TXA2
Fibrinogen von Willebrand factor
Indomethacin
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
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Platelet preparation, aggregation and dense
granule secretion
Human platelet preparation and aggregation assays were per-
formed using standard protocols. After informed consent had
been obtained, blood was collected from healthy, aspirin-free
human volunteers into a syringe containing 4% citrate (1:10
ratio). The citrated whole blood was mixed with an equal
volume of physiological saline (0.9% NaCl) and was used for
impedance aggregometry. The blood was centrifuged for
20 min at 102× g at room temperature to obtain platelet-rich
plasma (PRP) for aggregation, flow cytometry, clot retraction
and cyclic nucleotide assays. Further centrifugation of PRP
[with 125 ng·mL–1 prostaglandin I2 (PGI2)] at 1413× g for
10 min resulted in a platelet pellet that was re-suspended in
modified Tyrodes-HEPES buffer (134 mM NaCl, 2.9 mM KCl,
0.34 mM Na2HPO4·12H2O, 12 mM NaHCO3, 20 mM HEPES
and 1 mM MgCl2, pH 7.3) and washed by centrifuging again
at the same speed for 10 min. The resulting platelet pellet was
re-suspended in modified Tyrodes-HEPES buffer to a final
density of 4 × 108 cells·mL−1 for aggregation and ATP secretion
assays.
Platelet aggregation assays were performed by optical
aggregometry using cross-linked collagen-related peptide
[CRP-XL, a selective agonist for the platelet collagen recep-
tor glycoprotein (GP) VI, from Prof R Farndale (University
of Cambridge)], collagen (Horm collagen, Nycomed, Linz,
Austria) and thrombin (Sigma Aldrich, Poole, UK) in the
presence or absence of various concentrations of nobiletin
(Sigma Aldrich; dissolved in DMSO to prepare stock solu-
tions). The final concentration of DMSO used as required
was 0.01% (v/v), which did not affect platelet function and
was used as vehicle control. Similarly, dense granule secre-
tion was measured by monitoring the level of ATP released
from washed platelets upon activation with CRP-XL using a
luciferin-luciferase luminescence substrate (Chrono-log,
Havertown, PA, USA) by luminescence aggregometry. All the
aggregation assays (optical, impedance and luminescence)
were performed using Chrono-Log Model 700 Whole Blood/
Optical-Lumi Aggregometer.
Statistical analysis
The data obtained from aggregation, fibrinogen binding,
α-granule secretion and in vitro thrombus formation assays
were analysed using non-parametric repeated measures
ANOVA (Friedman test). Median fluorescence intensity values
obtained with fibrinogen binding and α-granule secretion
assays were converted into percentages for comparison of
controls with nobiletin-inhibited samples. Data obtained
from dense granule secretion, clot retraction, spreading and
cyclic nucleotide assays were analysed using parametric
repeated measures ANOVA. Data from calcium mobilization
experiments were analysed by ‘R’ statistical software and
the percentage of maximum level of calcium release was
analysed using non-parametric repeated measures ANOVA
(Friedman test). Tail bleeding assay data were analysed
using t-test. All the statistical analyses were performed
using GraphPad Prism (version 5.04) from GraphPad Soft-
ware Inc. (La Jolla, CA, USA).
Results
Nobiletin inhibits human platelet activation
Optical aggregometry was used to analyse the effects of nobi-
letin on platelet function upon activation with collagen,
CRP-XL and thrombin. Washed human platelets were incu-
bated with vehicle (0.01% DMSO) or nobiletin (6.25, 12.5, 25,
50 and 100 μM) for 5 min before stimulation with collagen
(1 μg·mL−1) for up to 5 min (Figure 1A) in an optical aggregom-
eter. Nobiletin reduced platelet aggregation in a
concentration-dependent manner at 5 min (Figure 1A and B)
with 95% inhibition achieved at 100 μM. The inhibitory
effects of nobiletin were reduced modestly when a higher
concentration of collagen (5 μg·mL−1) was used (Figure 1C and
D). Since collagen activates platelets by binding both glyco-
protein VI (GPVI) and integrin α2β1, a GPVI-selective agonist,
CRP-XL, was used in aggregation assays to determine whether
the inhibition of platelet aggregation occurred through the
blockade of GPVI signalling. Platelet aggregation stimulated
with CRP-XL (0.5 μg·mL−1) was also inhibited by nobiletin in a
concentration-dependentmanner (Figure 1E and F). Similar to
collagen, a higher concentration of CRP-XL (1 μg·mL−1)
reduced the level of inhibition induced by nobiletin
(Figure 1G and H). In order to determine whether nobiletin is
able to affect the signalling cascades activated by G-protein
coupled receptors, aggregation assays were performed using
thrombin as an agonist. A concentration of 0.1 U·mL−1 of
thrombin was chosen to obtain similar levels of aggregation as
obtained with other agonists such as collagen (1 μg·mL−1) and
CRP-XL (0.5 μg·mL−1). Thrombin (0.1 U·mL−1)-stimulated
platelet activation was inhibited by nobiletin only at higher
concentrations (50, 100, 150 and 200 μM; Figure 1I and J).
Lower concentrations of nobiletin did not inhibit thrombin-
induced platelet aggregation (data not shown).
Some dietary flavonoids such as quercetin (Wright et al.,
2012) and tangeretin (Vaiyapuri et al., 2013) have been
shown to bind plasma proteins, and therefore, the effect of
nobiletin on platelet activation in PRP was examined to
compare its effects with washed platelets. Collagen
(1 μg·mL−1)-induced platelet aggregation in PRP was inhibited
by nobiletin in a concentration-dependent manner to a
similar extent to that observed with washed platelets
(Figure 1K and L). This suggests that the effects of nobiletin at
this concentration are not adversely affected by the presence
of plasma proteins. To understand if the effects of nobiletin in
collagen-induced platelet aggregation are dependent on sec-
ondary activation mediated through molecules that are syn-
thesized and released from platelets, further aggregation
assays were performed using indomethacin (an inhibitor of
COX, which prevents TXA2 synthesis)-treated washed plate-
lets. CRP-XL (0.5 μg·mL−1)-induced aggregation was reduced
significantly by nobiletin in indomethacin (10 μM)-treated
platelets (Figure 1M and N) indicating that the effects of
nobiletin are not fully dependent on the inhibition of the
effects of secondary mediators such as TXA2. To further
understand the effects of nobiletin in whole blood in the
presence of other cells such as red blood cells and leukocytes,
impedance aggregometry was performed. Collagen at a con-
centration of 10 μg·mL−1 was used to obtain a similar level
of aggregation to 1 μg·mL−1 in washed platelets. Despite
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the higher concentration of collagen, nobiletin (50 μM
and above) reduced aggregation significantly (Figure 1O
and P). These analyses together indicate that nobiletin
predominantly inhibits GPVI-stimulated platelet activa-
tion, although it is able to modulate platelet activation
induced by other agonists such as thrombin, at higher
concentrations.
Integrin αIIbβ3-mediated inside-out signalling
is modulated by nobiletin
Platelet inside-out signalling to integrin αIIbβ3 plays an
essential role in the modulation of its conformation to
increase affinity for plasma fibrinogen and von Willebrand
factor (vWF) binding and consequent platelet aggregation
(Calderwood, 2004). In order to explore the effects of nobi-
letin in inside-out signalling that leads to the modulation
of integrin αIIbβ3 affinity, fibrinogen binding was measured
by flow cytometry in the presence or absence of nobiletin.
Consistent with platelet aggregation, CRP-XL (1 μg·mL−1)-in-
duced fibrinogen binding in PRP was inhibited significantly
at all concentrations of nobiletin used (6.25, 12.5, 25, 50,
100 and 200 μM; Figure 2A and Supporting Information
Fig. S1A).
Nobiletin inhibits platelet granule secretion
Platelet degranulation is an important step towards thrombus
formation as the released granule contents enhance rapid
activation of platelets through paracrine/autocrine actions
Figure 1
Nobiletin inhibits agonist-induced platelet activation. Human-washed platelet aggregation performed in the presence or absence of various
concentrations of nobiletin was monitored for 5 min by optical aggregometry following stimulation with 1 μg·mL−1 (A and B) and 5 μg·mL−1
collagen (C and D), 0.5 μg·mL−1 (E and F) and 1 μg·mL−1 CRP-XL (G and H) and 0.1 U·mL−1 thrombin (I and J). Similarly, the effects of nobiletin
on PRP were analysed following stimulation with 1 μg·mL−1 collagen (K and L). Indomethacin (10 μM)-treated platelets were stimulated with
0.5 μg·mL−1 CRP-XL in the presence and absence of nobiletin (M and N). Whole blood aggregation was performed using 10 μg·mL−1 collagen in
the presence and absence of nobiletin by impedance aggregometry (O and P). Cumulative data represent mean values ± SD (n = 3), the level of
aggregation obtained at 5 min with vehicle-treated samples (0 μM) was taken as 100%. The P-values shown in the figure are calculated by
non-parametric repeated measures ANOVA (Friedman test; ****P < 0.0001).
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(Gibbins, 2004). Platelet α-granules are rich in proteins such
as fibrinogen, vWF and P-selectin and dense granules are rich
in non-proteinaceous substances such as ADP, ATP and
calcium. To assess the ability of nobiletin to inhibit platelet
α-granule secretion, P-selectin exposure on the surface of
platelets upon stimulation with CRP-XL was measured by
flow cytometry. Different concentrations of nobiletin were
pre-incubated with human PRP prior to activation with
Figure 2
Nobiletin modulates platelet inside-out signalling, granule secretion and calcium mobilization. The effect of nobiletin on CRP-XL (1 μg·mL−1)-
induced fibrinogen binding (A) and P-selectin exposure (B) in PRP was measured by flow cytometry. The median fluorescence intensity values were
converted into percentages for comparison. The level of fibrinogen binding or P-selectin exposure with vehicle controls was taken as 100%. Data
represent mean ± SD (n = 5) and the P-values shown were calculated using non-parametric repeated measures ANOVA (Friedman test). Similarly,
the effect of nobiletin on dense granule secretion upon stimulation with CRP-XL (1 μg·mL−1) was measured in washed platelets (C and D). The
level of ATP obtained with vehicle controls was taken as 100%. Data represent mean ± SD (n = 4) and the P-values shown were calculated using
parametric repeated measures ANOVA. Fluo4-NW dye labelled human PRP was stimulated with 1 μg·mL−1 CRP-XL in the presence of 50 or 100 μM
nobiletin or vehicle control and the intracellular calcium levels were measured by flow cytometry (E). Traces shown are representative of four
separate experiments. The inhibition of intracellular calcium levels was calculated by comparing the levels obtained at 5 min (F) in the presence
or absence (taken as 100%) of nobiletin. Data represent mean ± SD (n = 4). The P-values shown in the figure were as calculated by using
non-parametric repeated measures ANOVA (Friedman test; ***P < 0.001 and ****P < 0.0001). AU represents arbitrary units.
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CRP-XL (1 μg·mL−1) and analysis of P-selectin exposure. Nobi-
letin inhibited significantly P-selectin exposure at all concen-
trations used in PRP (Figure 2B and Supporting Information
Fig. S1B). Maximal inhibition of approximately 50% was
obtained with 200 μM nobiletin. Similarly, the level of ATP
secreted from washed platelets assayed in parallel with aggre-
gation was inhibited by nobiletin upon stimulation with
CRP-XL (1 μg·mL−1) in a concentration-dependent manner
(Figure 2C and 2D). The level of inhibition observed in dense
granule secretion was larger than that of α-granule secretion,
which is likely due to different conditions (washed platelets,
stirring and 37°C for dense granule secretion; PRP, non-
stirring and room temperature for α-granule secretion) used
in these two assays. Together these data suggest that nobiletin
is able to reduce platelet granule secretion and thereby
control platelet activation.
Intracellular calcium mobilization is
modulated by nobiletin
An elevation of intracellular calcium levels in platelets is
important for the regulation of thrombus formation, reor-
ganization of the actin cytoskeleton necessary for shape
change (Hathaway and Adelstein, 1979), degranulation and
integrin αIIbβ3-mediated signalling (Shattil and Brass, 1987).
To analyse the effects of nobiletin on intracellular calcium
mobilization, this was measured in human platelets (PRP) by
flow cytometry. CRP-XL (1 μg·mL−1)-activated cytoplasmic
calcium levels were inhibited significantly by nobiletin (50
and 100 μM). Maximum inhibition of approximately 40%
was achieved with 100 μM nobiletin (Figure 2E and 2F). The
initial acceleration rate of calcium elevation was inhibited
substantially by nobiletin (Figure 2E). These data suggest that
nobiletin affects the elevation of intracellular calcium levels
to modulate platelet function.
Nobiletin affects integrin αIIbβ3-mediated
outside-in signalling
Following binding to fibrinogen, integrin αIIbβ3 clustering
transduces signals (outside-in signalling) into platelets to
allow spreading and in the latter phase of its formation, clot
retraction (Calderwood, 2004). The modulatory effects of
nobiletin on integrin αIIbβ3-mediated outside-in signalling
were analysed by measuring clot retraction and platelet
spreading under static conditions. Clot formation was initi-
ated by adding thrombin to PRP in the absence or presence of
nobiletin (12.5, 25, 50 and 100 μM), and the rate of clot
retraction was monitored over 2 h by measuring the remain-
ing clot weight. Although the initial clot formation was
normal in vehicle and nobiletin-treated samples, clot retrac-
tion was reduced significantly in the presence of nobiletin
(100 μM) at 2 h compared with the control samples
(Figure 3A and 3B). Similarly, nobiletin-treated (100 μM)
platelets were unable spread on fibrinogen to a similar extent
to control platelets at 45 min. Most nobiletin-treated platelets
failed to progress beyond filopodia formation with only a few
cells progressing to lamellapodia formation and full spread-
ing (Figure 3C and 3D). These data suggest that outside-in
signalling through integrin αIIbβ3, which controls the coor-
dinated process of clot retraction and platelet spreading on
fibrinogen, is affected by nobiletin.
Nobiletin limits thrombus formation in vitro
Given the dramatic effects of nobiletin on platelet function,
its effects on thrombus formation were assessed in vitro in
whole blood under arterial flow conditions. Fluorescently
labelled (DiOC6) human blood was pre-incubated with
vehicle control or different concentrations of nobiletin (12.5,
25, 50 and 100 μM) and perfused over collagen-coated Vena8
biochips for 10 min at a shear rate of 20 dynes·cm−2. Normal
progression of thrombus formation was observed in vehicle-
treated samples, whereas a clear reduction in thrombus
volume and fluorescence intensity (Figure 4A and 4B) was
observed at all concentrations of nobiletin used. These data
suggest that nobiletin is able to reduce both initial platelet
adhesion and subsequent thrombus formation.
Nobiletin extends bleeding time in mice
To analyse the effects of nobiletin on haemostasis, tail bleed-
ing assays were performed on mice in the presence of vehicle
[DMSO (0.01%)] or nobiletin (at estimated 50 μM concentra-
tion based on the mouse weight and respective volume of
blood). Vehicle-treated mice bled between 98 and 372 s,
whereas administration of nobiletin extended the bleeding
to between 278 and 1200 s (Figure 4C). Four of the seven
nobiletin-treated mice bled for 1200 s (when the assay was
terminated). These data suggest that nobiletin is able to
modulate haemostasis in mice, consistent with the effects
observed on thrombus formation.
Nobiletin blocks PKB (Akt) activation
Since collagen and CRP-XL-stimulated platelet activation was
affected by nobiletin, the phosphorylation levels of different
signalling proteins involved in the GPVI pathway were ana-
lysed. Washed human platelets were stimulated at 37°C in an
aggregometer under conditions (in presence of 1 mM EGTA,
10 μM indomethacin and 2 U·mL−1 apyrase) that disfavour
platelet aggregation with CRP-XL (1 μg·mL−1) in the presence
of various concentrations of nobiletin (12.5, 25, 50, 100, 150
and 200 μM) or vehicle control, and lysates were prepared to
analyse the phosphorylation of different signalling proteins.
Total tyrosine phosphorylation (Figure 5A) and the phospho-
rylation of individual proteins such as Syk (pY323) and LAT
(pY200; Figure 5B) were not affected by nobiletin. However,
tyrosine phosphorylation of PLCγ2 (pY759) was diminished
at all concentrations of nobiletin used (Figure 5B). Similarly,
the serine phosphorylation of PKB (or Akt) (pS473) was also
affected in a concentration-dependent manner by nobiletin
(Figure 5B). Although the phosphorylation levels were quan-
tified under non-aggregation conditions, the level of inhibi-
tion of phosphorylation of PLCγ2 and Akt were similar to the
inhibitory effects observed on platelet aggregation at the
same concentration of agonist (Figure 1G and 1H). For
example, 12.5 μM of nobiletin inhibited around 20–30% of
CRP-XL-induced platelet aggregation and phosphorylation of
PLCγ2 and Akt. These data suggest that nobiletin may not
influence the immediate effectors within the GPVI pathway
(such as Syk and LAT) although it can modulate the later
signalling events controlled by PLCγ2 and Akt, which are
shared with activation mechanisms stimulated by other ago-
nists. The inhibitory effects of nobiletin on PLCγ2 and Akt
phosphorylation indicate its potential effect on PI3K-
mediated platelet signalling.
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Nobiletin elevates platelet cGMP levels
Under physiological conditions, endothelium-derived nitric
oxide (NO) and PGI2 inhibit platelet function by elevating
platelet cGMP and cAMP levels respectively. Since plant fla-
vonoids such as tangeretin have been shown to act on cyclic
nucleotide signalling (Ok et al., 2012), the effects of nobiletin
on the levels of cGMP and cAMP in platelets were analysed in
the presence of vehicle control or different concentrations
(50, 100, 150 and 200 μM) of nobiletin. The levels of cGMP
(Figure 6A) and cAMP (Figure 6B) were unaltered upon stimu-
lation with CRP-XL (1 μg·mL−1), but the addition of nobiletin
elevated cGMP levels significantly. Lower concentrations (less
than 50 μM) of nobiletin did not increase the cGMP levels
significantly (data not shown). cAMP levels, however,
remained unaltered in the presence of all the concentrations
of nobiletin used. To explore whether the elevation of cGMP
levels by nobiletin is dependent on activation by CRP-XL, the
level of cGMP was measured in resting platelets incubated
with nobiletin (200 μM) for 5 min. Platelet cGMP levels were
increased in platelets treated with nobiletin alone (Figure 6A)
indicating that cGMP elevation is not dependent on agonist
stimulation or platelet activation. These data suggest that
nobiletin may inhibit platelet function through the elevation
of cGMP and not through cAMP.
To further understand the effects of nobiletin in platelets
through the elevation of cGMP levels, aggregation assays
were performed in the presence and absence of a soluble
guanylate cyclase inhibitor ODQ and a cGMP-dependent
PKG inhibitor (Rp-8-bromo-β-phenyl-1,N2-ethenoguanosine
3′,5′-cyclic monophosphorothioate sodium salt [Rp-8-Br-PET-
cGMPS]). Pre-incubation of platelets either with ODQ
(20 μM) or the PKG inhibitor (30 μM) did not cause a reduc-
tion in CRP-XL (0.5 μg·mL−1)-induced platelet aggregation.
However, both of these inhibitors reversed the inhibitory
actions of nobiletin (50 μM) upon activation with CRP-XL
(Figure 6C–F). These data further confirm that the actions of
nobiletin in platelets are at least in part explained by its
ability to modulate cGMP signalling.
Vasodilator-stimulated phosphoprotein (VASP) is a sub-
strate for cAMP- and cGMP-dependent PKs that mediate
cAMP- and cGMP-dependent inhibitory signalling in plate-
lets respectively (Butt et al., 1994; Li et al., 2003b). Upon
elevation of cAMP, the cAMP-dependent PKA phosphorylates
VASP at position S157, whereas increased levels of cGMP
result in phosphorylation of S239 in VASP by cGMP-
dependent PKG (Li et al., 2003a,b). To confirm the ability of
nobiletin to modulate cyclic nucleotide signalling, the phos-
phorylation of VASP was assessed using phospho-specific
Figure 3
Integrin αIIbβ3-mediated outside-in signalling is inhibited by nobiletin. The effect of various concentrations of nobiletin (12.5, 25, 50 and 100 μM)
on clot retraction was analysed in vitro using human PRP (A and B). (A) Representative image of clot retraction at 2 h in the presence or absence
of different concentrations of nobiletin. Data in (B) represent mean ± SD (n = 4) of clot weights measured at 2 h. Washed human platelets were
allowed to spread for 45 min in the presence and absence of 100 μM nobiletin on 100 μg·mL−1 fibrinogen-coated cover glasses and stained with
Alexa fluor 488 labelled phalloidin prior to analysis using a Nikon A1-R-confocal microscope. The images shown in (C) are representative
of multiple images acquired from four separate experiments. The images were analysed by ImageJ and the number of platelets found at different
states of platelet spreading were calculated (D). The P-values were calculated using parametric repeated measures ANOVA (***P = <0.001 and
****P = <0.0001).
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antibodies upon stimulation with CRP-XL (1 μg·mL−1).
Immunoblot analysis showed that nobiletin increased the
phosphorylation of VASP at S239 (Figure 6G), but only small
changes were observed in phosphorylation of position S157
(Figure 6H). These data suggest that nobiletin may modulate
the inhibitory signalling mediated through cGMP and PKG in
platelets.
Discussion
A better understanding of the relationship between plant
flavonoids and platelet function may aid in the development
of improved strategies to treat cardiovascular diseases. In this
study, we characterized nobiletin, which is a polymethox-
ylated flavonoid structurally similar to tangeretin present in
Figure 4
Nobiletin limits thrombus formation in vitro and extends bleeding time in mice. DiOC6 labelled human blood was pre-incubated with vehicle or
different concentrations of nobiletin and perfused over collagen-coated Vena8 BioChips. Images were obtained every 30 s for up to 10 min and
representative images (at 0, 2, 4, 6, 8 and 10 min) are shown in (A). The fluorescence intensity of thrombi obtained in the absence of nobiletin
was taken as 100% and compared with the levels obtained with different concentrations of nobiletin (B). Data represent mean ± SD (n = 4). The
P-values shown in the figure are as calculated by non-parametric repeated measures ANOVA (Friedman test; ****P < 0.0001). The effect of nobiletin
(estimated 50 μM) on haemostasis in mice was analysed by measuring the bleeding time after removal of 1 mm of tail tip. The bleeding time
obtained with vehicle-treated group was compared with nobiletin-treated mice (C). Data represent mean ± SD (n = 7 mice for vehicle control or
nobiletin-treated group). The significance between control and treated groups, and the P-values were calculated by Student’s t-test.
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the peel of citrus fruits, and analysed its anti-platelet effects.
Nobiletin was shown to have anti-adhesive properties in rat
platelets (Sempinska et al., 1977; Robbins, 1988), and reduced
death rates in rats by ADP induced thrombosis at 8 mM
concentration (Robbins, 1973). However, these previous
studies did not explore the mechanism of action through
which nobiletin exerts its effects in platelets particularly in
humans. In our previous study, we demonstrated the effects
of a citrus flavonoid, tangeretin on the modulation of platelet
function (Vaiyapuri et al., 2013). Tangeretin affected platelet
function by elevating cGMP levels and inhibiting PI3K-
mediated signalling cascades.
In this study, we report that nobiletin inhibited platelet
activation upon stimulation with collagen and CRP-XL in a
concentration-dependent manner with notable levels of
reduction achieved at as low as 6.25 μM. Increasing concen-
trations of agonists were able to partially overcome the
inhibitory effects of nobiletin, confirming that it does not
show any toxic effects to the platelets. Platelet activation
stimulated with a GPCR agonist, thrombin, was, however,
only inhibited at higher concentrations of nobiletin (as high
as 50 μM required to obtain a significant reduction) indicat-
ing that it has increased potency for the inhibition of GPVI
dependent pathways. Similar inhibitory effects on GPVI and
thrombin induced platelet activation were observed with tan-
geretin although at lower concentrations (Vaiyapuri et al.,
2013). These results indicate that nobiletin may be less potent
than tangeretin, although it maintained similar levels of inhi-
bition in PRP in the presence of plasma proteins. A number of
other plant-derived flavonoids such as quercetin, apigenin
and luteolin have been shown to inhibit agonist-induced
platelet aggregation at various concentrations (Hubbard et al.,
2003; 2004; Lill et al., 2003; Wright et al., 2010). Consistent
with the inhibition of aggregation, nobiletin was able to
inhibit the affinity modulation of integrin αIIbβ3 to favour
platelet aggregation. In addition, nobiletin inhibited platelet
granule secretion similar to tangeretin and other flavonoids.
A number of flavonoids have been shown to inhibit
several enzymes, which regulate normal cellular functions
such as tyrosine kinases, phospholipase As (PLAs), lipoxyge-
nases, COXs and phosphodiesterases (Benavente-Garcı’a
et al., 1997; Benavente-Garcia and Castillo, 2008; Wright
et al., 2012). Quercetin and catechin were able to inhibit the
phosphorylation of serine/threonine kinases, extracellular
signal–related kinase 1/2, c-Jun N-terminal kinase, MAPK and
Akt in vascular smooth muscle and endothelial cells (Wright
et al., 2012). Similarly, the flavonoids present in purple grape
juice were shown to partially inhibit the phosphorylation of
PKC in platelets (Freedman et al., 2001). Since nobiletin
inhibited collagen-induced platelet activation, further analy-
ses of the signalling proteins involved in the GPVI pathway
was performed and revealed that it did not affect early sig-
nalling effector molecules such as Syk and LAT. Nobiletin did
however diminish the activation of later signalling modula-
tors such as AKT and PLCγ2, both associated with PI3K sig-
nalling to regulate platelet function, particularly calcium
mobilization. Consistent with diminished PI3K signalling,
reduced calcium levels and subsequently retarded integrin
αIIbβ3-mediated outside-in signalling (clot retraction and
platelet spreading) were observed upon treatment with nobi-
letin. The inhibition of PLCγ2 and AKT by nobiletin was also
observed in other cell types such as liver cancer cells (Shi
et al., 2013). Together, these inhibitory effects of nobiletin
resulted in reduced thrombus formation in vitro under arterial
flow conditions.
Experiments to dissect the direct and indirect actions of
these citrus flavonoids on the various components of PI3K
signalling may reveal specific targets in the modulation of
Figure 5
Nobiletin inhibits phosphorylation of PLCγ2 and PKB (Akt). Washed human platelets were stimulated with CRP-XL (1 μg·mL−1) in the absence or
presence of various concentrations of nobiletin before the analysis by immunoblotting using anti-phosphotyrosine antibody (A) and phospho-
specific antibodies for proteins involved in the GPVI pathway such as Syk pY323, LAT pY200, PLCγ2 pY759 and Akt pS473 (B). Total level of 14-3-3ζ
was measured on each sample as a loading control. The blots shown in the figure are representative of four separate experiments. R represents
resting platelets. Data presented in (B) represent mean ± SD (n = 4) and P-values were calculated using non-parametric repeated measures ANOVA
(Friedman test; ****P < 0.0001).
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Figure 6
Nobiletin elevates cGMP levels and increases VASP (S239) phosphorylation. The levels of cGMP (A) and cAMP (B) were measured in platelets (PRP)
upon stimulation with CRP-XL (1 μg·mL−1) using ELISA kits in the presence or absence of various concentrations of nobiletin. The concentration of
cGMP and cAMP was calculated based on standard curves. R, resting; C, CRP-XL-treated platelets. Data represent mean ± SD (n = 4) and P-values
were calculated using parametric repeated measures ANOVA (****P < 0.0001). Platelet aggregation was measured using CRP-XL (0.5 μg·mL−1)
together in the presence and absence of 20 μM ODQ, a soluble guanylate cyclase inhibitor (C and D) or 30 μM PKG inhibitor (Rp-8-Br-PET-
cGMPS) (E and F) and 50 μM nobiletin for 5 min. C, O, P and N represent CRP-XL, ODQ, PKG inhibitor and nobiletin respectively. The level of
aggregation obtained with CRP-XL at 5 min was taken as 100% to calculate the percentage of inhibition. The data from C + N were compared
with C and C + O/P + N were compared with C + N. Data represent mean ± SD (n = 3) and P-values were calculated using Student’s t-test as shown
(**P < 0.01 and ***P < 0.001). The effect of various concentrations of nobiletin on phosphorylation of VASP [at positions pS239 (G) and pS157
(H)], a substrate for cyclic nucleotide-dependent PKs, was analysed in washed platelets upon stimulation with CRP-XL (1 μg·mL−1) by immuno-
blotting. The blots are representative of four separate experiments. Data represent mean ± SD (n = 4) and P-values were calculated using
non-parametric repeated measures ANOVA (Friedman test; ****P < 0.0001).
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platelet function. The inhibition of PI3K signalling was also
observed with other flavonoids such as quercetin (Matter
et al., 1992), which led to the development of LY294002, a
commonly used PI3K inhibitor (Vlahos et al., 1994). Due to
the broad spectrum nature of flavonoids on different aspects
of cell regulation (Wright et al., 2012), it is entirely possible
for nobiletin to have other target mechanisms to inhibit
platelet function. Flavonoids such as apigenin and luteolin
have shown to antagonize TXA2 receptors in order to inhibit
platelet function (Lill et al., 2003), and therefore, nobiletin
may also have additional targets that may influence on the
secondary activation of platelets.
The ability of flavonoids to inhibit phosphodiesterases
(PDE; Wright et al., 2012), which are involved in the
hydrolysis of cyclic nucleotides such as cAMP and cGMP
(Francis et al., 2011), suggests that flavonoids may also
modulate platelet function through other inhibitory mecha-
nisms. Nobiletin increased the cGMP levels and VASP phos-
phorylation at S239, which is phosphorylated by PKG,
while it neither increased the cAMP levels nor phosphoryla-
tion of VASP at S157, which is regulated by PKA. The
increased levels of VASP phosphorylation may directly
inhibit platelet function mediated through the phosphor-
ylation of myosin light chain kinase resulting in impaired
calmodulin binding and therefore reduce cytoskeletal reor-
ganization essential for platelet shape change (Onselaer
et al., 2014). In addition, VASP phosphorylation is able to
inhibit the activation of integrin αIIbβ3 and suppress
the release of intracellular calcium through inhibiting
IP3 receptor activation (Geiger, 2001). We have previously
shown that tangeretin was able to increase the levels of
cGMP although it did not alter the cAMP levels or inhibit
PDE activity (Vaiyapuri et al., 2013), indicating that tangere-
tin elevates cGMP levels through increased production
rather than its reduced hydrolysis. Purple grape juice
and flavonoid derivatives have been shown to increase
platelet derived NO production in order to inhibit platelet
function (Freedman et al., 2001). Elevated levels of NO in
platelets are capable of causing an increase in cGMP
levels, which in turn activate PKG to phosphorylate its sub-
strate VASP at position S239 (Butt et al., 1994). It is pres-
ently unclear whether the effects that we observed
are mediated by direct actions of nobiletin on NO produc-
tion, or cGMP levels. It is presently unclear whether the
effects of nobiletin on PI3K and cGMP signalling are mecha-
nistically linked or whether they represent separate modes
of action.
Better understanding of the structure–function relation-
ships of flavonoids will reveal their selectivity for target
molecules (Wright et al., 2012), and will also enable the
understanding of differences between the specificity and effi-
ciency of nobiletin and tangeretin. While structurally similar,
a difference at an O-methyl group on the B ring results in
considerable changes in their inhibitory effects observed in
PRP, suggesting the importance of this methyl group in deter-
mination of its ability to bind plasma proteins.
The polymethylated structure of nobiletin has been sug-
gested to maintain its stability and enable resistance against
the metabolic changes such as alterations by the cytochrome
P450 system, UDP-glucurosyltransferases and sulphotrans-
ferases (Walle, 2007). The most common metabolic changes
observed in nobiletin are the demethylation on the C4
ring in its structure (Yasuda et al., 2003). The extended half-
life of nobiletin compared with tangeretin in the
circulation (Walle, 2007; Manthey et al., 2011) suggests this
may be potentially administered in order to avail longer
bioavailability.
In this study, we demonstrate that 12.5 μM nobiletin is
able to significantly inhibit platelet function in vitro in
washed platelets, PRP and whole blood. A concentration of
50 μM was shown to moderately affect haemostasis in mice.
Tail bleeding assays were performed at 37°C by maintaining
the animal on a heated mat. The use of anaesthetics may
have effects on platelet function and therefore in haemo-
stasis; however, the parallel comparison of vehicle control
and nobiletin-treated mice alleviates this issue. A pharma-
cokinetic study previously reported (Manthey et al., 2011)
that concentrations of tangeretin of around 6.2 μM (includ-
ing known metabolites) and nobiletin 22.4 μM in rodents
were achievable upon oral administration of 50 mg·kg−1 of
body weight. This indicates that the ingestion of around
100 mg·kg−1 may reach approximately 50 μM of nobiletin in
plasma and affect haemostasis to a similar extent to that
observed in this study. As reported in the previous study,
the bioavailability of nobiletin even after 12 h of oral
administration was maintained above a concentration of
approximately 5 μM. The half-life of nobiletin, however,
upon the administration through the i.v. route has yet to be
explored. Although one would imagine that it is unlikely
for these levels of nobiletin and tangeretin to be achieved
through regular dietary intake, many additional flavonoids
are present in most diets. It may also be possible to achieve
the required levels of these flavonoids by regular oral sup-
plementation as suggested previously in rodents. Indeed, a
pilot human study reported quercetin to reach 10 μM
through oral dietary supplementation (Hubbard et al., 2006)
and this suggests that the regular intake of nobiletin
through supplementation might show similar effects, which
we observed in mice upon i.v. infusion of nobiletin. There-
fore, nobiletin and tangeretin, together with other bioactive
flavonoids, may collectively modulate platelet function in
order to reduce potential thrombosis risk. The effects of tan-
geretin and nobiletin, however, below the threshold of
detection in vivo, may still be relevant. Chronic ingestion of
nobiletin and tangeretin from diets may also result in a
cumulative effect on the reduction of platelet function over
a period of time. Diets rich in bioactive flavonoids also
result in intake of a range of complex mixtures of various
flavonoids such as quercetin, apigenin and luteolin that
may also be beneficial in reducing cardiovascular disease
incidence. We conclude that further investigation to explore
the therapeutic potentials of nobiletin and tangeretin may
enable the formulation of better therapeutic strategies to
reduce cardiovascular disease risk.
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